BALTIMORE, May 13, 2010 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated research coverage of Radient Pharmaceuticals Corporation (NYSE AMEX:RPC), a leading early stage cancer/oncology in-vitro diagnostic test kits provider.
Radient has won FDA approval for its lead product as a post-surgery colorectal cancer monitoring test and is the only approved product abroad for lung cancer detection and monitoring and as a general cancer screen. By year-end, Radient will submit an application for approval as a general cancer screen with the FDA, which would markedly expand its current billion dollar market opportunity. As part of its diagnostics focus, Radient is in the midst of monetizing non-core assets and business lines through divestitures and out-licensing.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines milestone events that he believes will serve as catalysts for the Company's shares.
"We view Radient as a stock that offers great value and potential for its existing operations, hidden but soon-to-be monetized value in its non-core assets, and home run potential with its next-gen product, should it be awarded FDA approval. A steady stream of news and events prior to FDA submission should serve as catalysts for the stock."
To view a summary of the report or download the report in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces stock market research reports. The Firm produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm's internally generated stock ideas while the Opportunity product reflects sponsored research reports. While performance is tracked separately, the same coverage criteria are utilized in determining coverage of all stocks in both research formats.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer. To download our research or for more information, visit www.goldmanresearch.com.
About Radient Pharmaceuticals Corporation: Radient Pharmaceuticals Corporation (NYSE AMEX:RPC) is an integrated In-Vitro Diagnostic (IVD) company devoted to the research, development, manufacturing, and marketing of diagnostic products. Radient's primary focus is on the early stage cancer/oncology diagnostic segment, with its lead product, Onko-Sure™. For more information, visit www.radient-pharma.com